On the quest for a better understanding of the molecular biology of SCCHN, researchers have focused on the introduction of targeted agents and on epidermal growth factor receptor (EGFR)-inhibitors in particular. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.